This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
An experimental ALS drug that grew out of basic and clinical research at Columbia University's Vagelos College of Physicians and Surgeons may soon become available for patients with a rare and aggressive form of the disease.
In September, Ionis and Otsuka Pharmaceutical, which developed the drug, called ulefnersen, announced that the phase 3 FUSION trial had met its primary endpoint: patients with FUS-ALS (caused by mutations in the FUS gene) who were treated with ulefnersen had a statistically significant improvement compared with those who received placebo in a combined measure of function and survival.
"This marks a historic success in our field—and a proud moment for all of us at Columbia University who are working to develop effective therapies for people with ALS and other neurodegenerative diseases," says Neil Shneider, director of the Eleanor and Lou Gehrig ALS Center at Columbia University. "This is the first-ever placebo-controlled trial of an ALS therapy targeting the underlying genetic cause of FUS-ALS, and the first time any ALS trial has met this challenging primary clinical endpoint."
For most patients with ALS, the cause of the disease cannot be identified. But for 1% to 2% of patients with ALS, the disease can be traced to mutations in the FUS gene.
"FUS-ALS can be highly aggressive and often strikes people in the very prime of their lives, including children, adolescents and young adults," says Shneider.
Source link







